BioXcel Therapeutics, Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
BioXcel Therapeutics, Inc. (BTAI) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $3.31 million for the 6-month period ending 2022-06-30, per its 10-Q filed 2022-08-11.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2022-08-11
- BioXcel Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2022-06-30 was $3.99M, a 2458.33% increase year-over-year.
- BioXcel Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2022-03-31 was -$676.00K, a 267.74% decline year-over-year.
- BioXcel Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2021-12-31 was $2.04M.
- BioXcel Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2021-09-30 was $2.25M, a 1246.11% increase year-over-year.
- BioXcel Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2021 was $4.85M, a 51.70% increase from fiscal 2020.
- BioXcel Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2020 was $3.20M, a 14.95% decline from fiscal 2019.
- BioXcel Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2019 was $3.76M, a 17.43% increase from fiscal 2018.
- BioXcel Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2018 was $3.20M, a 334.33% increase from fiscal 2017.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2022-06-30 | $3.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $3.31M 10-Q · filed 2022-08-11 | $5.36M derived: sum of 3 quarters · filed 2022-08-11 | $7.61M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2022-03-31 | -$676.00K 10-Q · filed 2022-05-09 | $1.37M derived: sum of 2 quarters · filed 2022-05-09 | $3.62M derived: sum of 3 quarters · filed 2022-05-09 | $3.77M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-12-31 | $2.04M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $4.29M derived: sum of 2 quarters · filed 2022-03-11 | $4.45M derived: sum of 3 quarters · filed 2022-08-11 | $4.85M 10-K · filed 2022-03-11 | ||||
| 2021-09-30 | $2.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $2.40M derived: sum of 2 quarters · filed 2022-08-11 | $2.81M 10-Q · filed 2021-11-10 | -$1.83M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-06-30 | $156.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $559.00K 10-Q · filed 2022-08-11 | -$4.07M derived: sum of 3 quarters · filed 2022-08-11 | -$3.91M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | $403.00K 10-Q · filed 2022-05-09 | -$4.23M derived: sum of 2 quarters · filed 2022-05-09 | -$4.06M derived: sum of 3 quarters · filed 2022-05-09 | -$169.00K derived: sum of 4 quarters · filed 2022-05-09 | ||||
| 2020-12-31 | -$4.63M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | -$4.47M derived: sum of 2 quarters · filed 2022-03-11 | -$572.00K derived: sum of 3 quarters · filed 2022-03-11 | $3.20M 10-K · filed 2022-03-11 | $3.03M 10-K · filed 2021-03-12 | |||
| 2020-09-30 | $167.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $4.06M derived: sum of 2 quarters · filed 2021-11-10 | $7.83M 10-Q · filed 2021-11-10 | $7.71M 10-Q · filed 2020-11-12 | $8.17M derived: sum of 4 quarters · filed 2021-11-10 | |||
| 2020-06-30 | $3.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $7.66M 10-Q · filed 2021-08-10 | $8.00M derived: sum of 3 quarters · filed 2021-08-10 | $8.27M derived: sum of 4 quarters · filed 2021-08-10 | ||||
| 2020-03-31 | $3.77M 10-Q · filed 2021-05-10 | $4.11M derived: sum of 2 quarters · filed 2021-05-10 | $4.38M derived: sum of 3 quarters · filed 2021-05-10 | $5.92M derived: sum of 4 quarters · filed 2021-05-10 | ||||
| 2019-12-31 | $336.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $606.00K derived: sum of 2 quarters · filed 2021-03-12 | $2.15M derived: sum of 3 quarters · filed 2021-03-12 | $3.76M 10-K · filed 2021-03-12 | $3.58M 10-K · filed 2020-03-09 | |||
| 2019-09-30 | $270.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $1.82M derived: sum of 2 quarters · filed 2020-11-12 | $3.42M 10-Q · filed 2020-11-12 | $3.25M 10-Q · filed 2019-11-14 | $6.04M derived: sum of 4 quarters · filed 2020-11-12 | |||
| 2019-06-30 | $1.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | $3.15M 10-Q · filed 2020-08-14 | $5.77M derived: sum of 3 quarters · filed 2020-08-14 | $6.42M derived: sum of 4 quarters · filed 2020-08-14 | ||||
| 2019-03-31 | $1.61M 10-Q · filed 2020-05-12 | $1.60M 10-Q · filed 2019-05-07 | $4.22M derived: sum of 2 quarters · filed 2020-05-12 | $4.88M derived: sum of 3 quarters · filed 2020-05-12 | $3.06M derived: sum of 4 quarters · filed 2020-05-12 | |||
| 2018-12-31 | $2.62M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-09 | $3.27M derived: sum of 2 quarters · filed 2020-03-09 | $1.46M derived: sum of 3 quarters · filed 2020-03-09 | $3.20M 10-K · filed 2020-03-09 | ||||
| 2018-09-30 | $653.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | -$1.16M derived: sum of 2 quarters · filed 2019-11-14 | $584.00K 10-Q · filed 2019-11-14 | $916.00K derived: sum of 4 quarters · filed 2019-11-14 | ||||
| 2018-06-30 | -$1.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | -$69.00K 10-Q · filed 2019-08-06 | -$70.00K 10-Q · filed 2018-08-08 | $263.00K derived: sum of 3 quarters · filed 2019-08-06 | $552.00K derived: sum of 4 quarters · filed 2019-08-06 | |||
| 2018-03-31 | $1.74M 10-Q · filed 2019-05-07 | $2.74M 10-Q · filed 2018-05-14 | $2.08M derived: sum of 2 quarters · filed 2019-05-07 | $2.36M derived: sum of 3 quarters · filed 2019-05-07 | $2.49M derived: sum of 4 quarters · filed 2019-05-07 | |||
| 2017-12-31 | $332.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | $621.00K derived: sum of 2 quarters · filed 2019-03-12 | $748.00K derived: sum of 3 quarters · filed 2019-03-12 | $737.00K 10-K · filed 2019-03-12 | ||||
| 2017-09-30 | $289.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $416.00K derived: sum of 2 quarters · filed 2018-11-09 | $405.00K 10-Q · filed 2018-11-09 | |||||
| 2017-06-30 | $127.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $116.00K 10-Q · filed 2018-08-08 | ||||||
| 2017-03-31 | -$11.00K 10-Q · filed 2018-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |